Fierce Pharma

FEBRUARY 8, 2024

Editor-in-Chief Ayla Ellison engages in a conversation with Fierce Pharma Marketing Senior Editor Ben Adams about the drugs likely to launch this year with the most significant sales potential by 2028.

Sales 189

Sales Pharma Marketing 189

Sales Talent

FEBRUARY 7, 2020

**The 2022 Sales Hiring Forecast has been released – check it out now!**. It’s time for the 6th installment of our annual sales hiring forecast. As there isn’t a hiring forecast specific for b2b sales roles, we started our own forecast in 2015 to help fill this gap. 2019 Sales Hiring in Review. 2020 Sales Hiring Forecast.

Sales 130

Sales B2B Sales Recruitment Marketing 130

European Pharmaceutical Review

MARCH 25, 2025

billion, alongside net sales royalties if HRS-5346 is approved. MSD intends to commit a further $8 billion of US capital investment by 2028, the firm shared. Ltd (Hengrui Pharma) has agreed to license its drug candidate HRS-5346 worldwide, excluding the Greater China region.As

Manufacturing 52

Manufacturing Pharma Recruitment Pharmaceutical 52

World of DTC Marketing

MARCH 17, 2021

sales until at least 2023 because 257 patent filings stand in the way. Another biologic, Enbrel, on the market since 1998, will not have its $5 billion in sales challenged until the end of 2028. For 2020, AbbVie’s handing its longtime CEO $24 million in total pay, up from 2019’s $21.6

Pharma 186

Pharma Competition Prescription Sales 186

Pharmaceutical Technology

SEPTEMBER 15, 2022

As a result of huge global sales of mRNA Covid-19 vaccines, the split in profits between Pfizer and BioNTech’s Comirnaty contributed towards revenues of $81.3bn and $22.4bn last year, respectively. Pfizer reaped $36.8bn from Comirnaty, the highest revenue generated from Covid-19 vaccine sales worldwide. YoY revenue growth.

Sales 108

Sales Competition Pharmaceutical Pharmaceutical research 108

Pharmaceutical Technology

JANUARY 25, 2023

It was an exceptional year for Moderna’s vaccine Spikevax, with forecast sales of $19.5bn in 2022. Currently, Spikevax is the second bestselling Covid-19 vaccine behind Pfizer’s Comirnaty, which is in the leading position, with forecast sales of $37bn in 2022.

Competition 59

Competition Sales Marketing Leads 59

pharmaphorum

JUNE 27, 2022

per share for Cambridge, Massachusetts-based Epizyme – valuing the US company at around $247 million – and is also promising a further contingent value right (CVR) payment of up to $1 per share if Tazverik (tazemetostat) achieves certain development and sales targets. Ipsen is offering $1.45 Ipsen’s CVR offer includes $0.30

Biopharma 111

Biopharma Sales Prescription FDA 111

pharmaphorum

AUGUST 8, 2022

As we reported this morning, the deal gives Pfizer already-approved SCD therapy Oxbryta (voxelator) – which industry watchers reckon could see a dramatic uptick in sales with Pfizer’s marketing muscle – plus a phase 3 antibody candidate, a phase 1 follow-up to Oxbryta that could offer improved dosing. per-share deal valuing GBT at $5.4

Marketing 111

Marketing Sales Pharma FDA 111

European Pharmaceutical Review

FEBRUARY 8, 2023

GlobalData predicts Bristol-Myers Squibb’s Breyanzi and Gilead’s Yescarta are set to have high annual sales in the forecast period. It is set to retain its market-leading position as the most lucrative CD19 CAR-T agent in NHL, with annual sales reaching $1.7 Peak sales are anticipated to reach $1.3 billion in 2031.

Marketing 98

Marketing Sales Physicians Patients 98

European Pharmaceutical Review

AUGUST 21, 2023

Lilly completes biopharma acquisitions GlobalData highlighted that Eli Lilly reported its synthetic peptide Mounjaro had $980 million in global sales in Q2. GSK Furthermore, biopharma firm GSK reported +4 percent and +11 percent ex COVID sales in the second quarter of 2023. Drugs Verzenio, Jardiance and Taltz led this result.

Biopharma 98

Biopharma Marketing Sales Medicine 98

Pharmaceutical Technology

JANUARY 30, 2023

According to GlobalData’s Drugs database, there were 22 prophylactic vaccines in development for COVID-19 with sales forecasts available in H2 2022. According to GlobalData’s Drugs database, there were 22 prophylactic vaccines in development for COVID-19 with sales forecasts available in H2 2022.

Sales 52

Sales Leads Competition Medicine 52

pharmaphorum

AUGUST 4, 2022

The $52-per-share offer would give Amgen a drug that some analysts have described as a pipeline in a pill with $1 billion-plus sales potential, and is a sizeable premium on ChemoCentryx’ pre-deal announcement share price of just over $24. billion bid to buy out the company.

Side effects 98

Side effects Sales Pharma Competition 98

European Pharmaceutical Review

JUNE 28, 2023

The treatment is expected to launch in 2028 in the US, EU, and Japan. If commercialisation is successful, obicetrapib is expected to value $619 million in sales by 2029, stated GlobalData. According to GlobalData, the CETP inhibitor obicetrapib is in the pipeline for dyslipidaemia. appeared first on European Pharmaceutical Review.

Patients 97

Patients Sales Medical Pharmaceutical 97

Every Ancillary

MAY 14, 2021

Most seasoned medical sales representatives have carried several different products or services over their careers. Between emerging technologies, expiring patents, and ever-changing insurance coverage, the role of a medical sales professional is to constantly adapt and learn new things. Gives you an area of expertise.

Medical sales 52

Medical sales Medical Sales Insurance 52

Pharmaceutical Technology

OCTOBER 5, 2022

According to GlobalData’s analyst consensus forecast, Yescarta is expected to reach peak sales of $1.8bn in 2028, and Kymriah is expected to reach sales of $686m in the same year.

Patients 111

Patients Sales Safety Manufacturing 111

Pharmaceutical Technology

MAY 26, 2023

These figures are only expected to grow in the coming years, with sales forecasted to reach over $150 billion by 2028. This high compound annual growth rate of 23.6% was powered by the advent of immune-checkpoint inhibitors, added Chalk. GlobalData is the parent company of Pharmaceutical Technology.

Marketing 105

Marketing Physicians Insurance Pharmaceutical 105

Quantified

OCTOBER 16, 2023

That’s especially been the case in the sales arena where, according to a recent McKinsey report , the effect of ChatGPT and similar generative AI technologies has been nothing short of revolutionary. For example, look at the following two prompts (you might want to try them for yourself): Write a sales email for our ABC Widget product.

Sales 52

Sales Training Sales Management B2B Sales 52

Pharmaceutical Technology

MAY 19, 2023

Rituxan received its first FDA approval in 1997 for the treatment of B-cell non-Hodgkin’s lymphoma (B-NHL) and reached peak global sales of $7.5bn in 2014. Rituximab biosimilars have since achieved notable commercial success, with global sales surpassing $900m collectively.

Sales 59

Sales Competition Marketing Patients 59

Pharmaceutical Technology

MAY 16, 2023

This growth is expected to continue, with a 62% growth in annual consensus sales forecast from 2023 to 2028, fuelled by the company’s semaglutide portfolio, according to GlobalData’s report, ‘Looking ahead to 2023 – the future of pharma’. Novo Nordisk reported an 18.2% million by 2029.

Marketing 52

Marketing Sales Pharma Leads 52

PM360

SEPTEMBER 21, 2023

Generic Drug Launches This year could see up to 50 generic drug approvals on brand pharmaceuticals worth more than $20 billion in sales, Casberg noted. billion in sales. The product had sales of roughly $800 million per year. The drug generated $2 billion in sales last year. “We’re

Management 105

Management Manufacturing Sales Competition 105

Pharmaceutical Technology

AUGUST 16, 2022

Enhertu has already achieved regulatory approval as a second-line therapy for metastatic or recurrent HER2-positive breast cancer, as well as HER2-positive gastric or gastroesophageal junction adenocarcinoma, with annual sales for these indications alone expected to exceed $1.3bn by 2028.

Food and Drug Administration 59

Food and Drug Administration Sales Patients Food 59

European Pharmaceutical Review

JANUARY 5, 2023

A 2022 market report forecasted that mRNA non-vaccine therapeutics are set to generate $2 billion in sales by 2028. The facility also offers potential for the development of vaccines for other respiratory illnesses, such as flu and respiratory syncytial virus (RSV). The future mRNA therapeutic market.

Manufacturing 59

Manufacturing Medicine Marketing Sales 59

PM360

JANUARY 24, 2025

The use of medicines worldwide grew by 14% over the past five years, and is expected to grow an additional 12% by 2028. Healthcare expenses in emerging markets are expected to grow and reach parity with developed nations. More patients are being treated with better medicines as healthcare infrastructures improve.

Marketing 52

Marketing Pharma Healthcare Healthcare 52

Pharmaceutical Technology

SEPTEMBER 2, 2022

According to GlobalData’s consensus analyst sales and forecast database, Carvykti is forecast to achieve the highest sales of the anti-BCMA biologics class, with $2.9 billion global sales expected by 2028, followed by Tecvayli with $2.6bn, which would mark a huge win for J&J in the MM space.

Food and Drug Administration 59

Food and Drug Administration Sales FDA Marketing 59

Pharmaceutical Technology

MAY 19, 2023

EyePoint Pharmaceuticals will also receive potential royalties on the combined net sales of Iluvien and Yutiq in the US from 2025 to 2028. The company made a $75m up-front cash payment to EyePoint Pharmaceuticals on the closure of the deal, and an additional $7.5m will be paid in equal quarterly instalments in 2024.

Food and Drug Administration 52

Food and Drug Administration Food Pharmaceutical Sales 52

Pharmaceutical Technology

NOVEMBER 8, 2022

These acquisitions could possibly add a minimum of $1bn in sales of Viatris by 2028. Subject to necessary closing conditions and approvals, Viatris anticipates concluding the Oyster Point takeover in the first quarter of next year. Famy Life Sciences has an ophthalmology portfolio that complements Viatris.

Food and Drug Administration 59

Food and Drug Administration Leads Food Pharma 59

pharmaphorum

AUGUST 2, 2022

According to McKinsey, global oncology sales are expected to hit $250 billion by 2024 and, despite the impact of COVID-19, the number of clinical trials starts reached record highs in 2021, stated IQVIA. billion in revenue last year.

Marketing 98

Marketing Prospecting Sales Pharma 98

PM360

SEPTEMBER 21, 2023

Over the next few weeks, manufacturers will submit a range of clinical, marketing, sales, pricing, and patient data, and then meet with CMS to discuss submissions later this fall. The IRA sets physician reimbursement of these products at the CMS-established MFP plus 6% versus current average sales price.

Manufacturing 111

Manufacturing Marketing Competition Physicians 111

Pharmaceutical Technology

DECEMBER 16, 2022

This therapy is currently in Phase II development and is expected to launch in the US and 5EU in 2027 and 2028, respectively. of 7MM sales. GlobalData’s report also covers a third pipeline candidate, quinagolide, a dopamine receptor antagonist being developed by Ferring Pharmaceuticals.

Marketing 59

Marketing Side effects Sales Safety 59

European Pharmaceutical Review

MAY 2, 2023

Avacincaptad pegol is forecasted to achieve sales of $1.09 billion in 2028, according to GlobalData’s Pharma Intelligence Center. The acquisition “has the potential to benefit patients worldwide suffering from blinding retinal diseases, including GA,” acknowledged Dr Pravin U Dugel, President of Iveric Bio.

Food and Drug Administration 52

Food and Drug Administration Pharma Sales FDA 52

pharmaphorum

OCTOBER 10, 2022

Merck has multibillion-collar sales expectations for sotatercept, which will be at the heart of a renewed push into cardiovascular disease therapies. .” “We are moving with urgency on our regulatory applications to bring this investigational therapy to these patients,” he added.

Sales 52

Sales FDA Pharma Competition 52

Pharmaceutical Technology

MARCH 23, 2023

This figure derives from net product sales in addition to revenues gained from royalties and licensing agreements. Most notably, Tivdak saw its sales rise dramatically, from $6m in 2021 to $63 million in 2022, with rapid drug uptake following its approval for cervical cancer in September 2021.

Sales 59

Sales Engineering Patients Marketing 59

Pharmaceutical Technology

JULY 12, 2022

The leading marketed CAR-T cell products, Gilead’s Yescarta (axicabtagene ciloleucel) and Novartis’ Kymriah (tisagenlecleucel), achieved $695m and $587m in sales respectively last year, demonstrating the high potential for sales of successful new cell therapies.

Leads 52

Leads Food and Drug Administration Marketing Sales 52

pharmaphorum

JANUARY 5, 2023

Recruiting and retaining talent is one of the biggest challenges facing the industry now through 2028, as the US Bureau of Labor Statistics expects life, physical, and social sciences to grow 7%. As the industry continues to grow and evolve, the demand for skilled labour is paramount. About the author.

Pharmaceutical 90

Pharmaceutical Recruitment Training Education 90

Pharmaceutical Technology

MARCH 30, 2023

In 2022, the company reported Keytuda sales of $20.9 As per GlobalData’s consensus forecasts, the drug is estimated to yield global sales of $34.79 billion in 2028. billion in its FY 2022 results. GlobalData is the parent company of Pharmaceutical Technology.

Food and Drug Administration 52

Food and Drug Administration FDA Sales Food 52

pharmaphorum

NOVEMBER 2, 2022

Abiomed makes the bulk of its $1 billion-plus annual sales from its Impella range of heart pumps, which are billed as the smallest such devices available in the world, and have enjoyed double-digit growth for several quarters as well as margins upwards of around 22%. Impella heart pump. Joaquin Duato.

Sales 52

Sales Medical Marketing Manufacturing 52

Pharmaceutical Technology

DECEMBER 11, 2022

GlobalData’s consensus analyst forecast database projects peak sales for pirtobrutinib to reach $892 million by 2028, and $4.8 billion for Calquence. GlobalData is the parent company of Pharmaceutical Technology.

FDA 59

FDA Patients Safety Pharmaceutical 59